My Profile

Search abstracts

Lewis Sheiner


2018
Montreux, Switzerland



2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
København, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 25 (2016) Abstr 5848 [www.page-meeting.org/?abstract=5848]


Oral: Growth modelling


B-16 Nick Holford Growth and decline of body size and composition – Prediction of the transition from pre-diabetes to Type 2 diabetes in humans

Nick Holford (1), Tim Kenealy (2)

(1) Department of Pharmacology and Clinical Pharmacology, University of Auckland, New Zealand (2) Department of General Practice, University of Auckland, New Zealand

Objectives: The most common consequence of obesity is the development of Type 2 diabetes. Body mass index (BMI) is widely used to quantify obesity but it is a size metric without a clear biological basis. Fat mass, on the other hand, is anatomically and physiologically identifiable. Increased fat has been suspected as the causal factor for developing Type 2 diabetes and decreased survival [1, 2]. The objectives of this study are:

  1. to describe the time course of growth and decline of body size and composition in pre-diabetic humans.
  2. to identify factors related to body size and composition predictive of the time to develop Type 2 diabetes.

Methods: A cohort of 21,002 adult pre-diabetic patients were followed in a New Zealand general practice setting. Total body weight (TBW), height (HT), sex, ethnicity and current smoking habit were recorded at each visit until a diagnosis of Type 2 diabetes was made or the study ended. Fat free mass and fat mass were predicted from weight, height and sex [3]. The clinical outcome event was the time to diagnosis of Type 2 diabetes. Mixed effect joint models of TBW, HT and time to event [4] were used for model selection and parameter estimation with NONMEM 7.3.

Results: There was a significant trend for TBW (-0.46 kg/y) and HT (-0.12 cm/y) to decrease with age. Significant covariates for baseline TBW were sex, smoking, and race and for rate of decline covariates were sex and smoking. The rate of loss of TBW was 13% faster in women and 33% faster in women smokers. Smaller effects were seen with HT. Predicted fat mass tended to increase in young adults before declining. The baseline hazard of developing Type 2 diabetes had a Gompertz distribution. Explanatory factors were sex, smoking, race and body size. The time course of fat mass was a significant predictor of the hazard.

Conclusions: We have developed a mixed effects model for growth in pre-diabetic humans. The time course of TBW and HT can predict changes in size metrics such as BMI and fat mass in this high risk population. The time to event model provides quantitative evidence for the lipotoxicity theory [2] of the pathogenesis of Type 2 diabetes. In a drug development setting these models can quantify the benefits of therapeutic goals based on weight reduction and be used to simulate more effective clinical trials [5].



References:
[1] McAuley, P.A., et al., Fitness, fatness, and survival in adults with prediabetes. Diabetes Care, 2014. 37(2): p. 529-36.
[2] Sivitz, W.I., Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression. Postgrad Med, 2001. 109(4): p. 55-9, 63-4.
[3] Janmahasatian, S., et al., Quantification of lean bodyweight. Clin Pharmacokinet, 2005. 44(10): p. 1051-65.
[4] Holford, N., A Time to Event Tutorial for Pharmacometricians. CPT: pharmacomet. syst. pharmacol., 2013. 2: p. e43 doi:10.1038/psp.2013.18.
[5] Holford, N., S.C. Ma, and B.A. Ploeger, Clinical trial simulation: a review. Clin Pharmacol Ther, 2010. 88(2): p. 166-82.